At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Varenicline OTC Trial on Efficacy and Safety
In Brief
A Phase 4 clinical trial evaluating 1.0mg Varenicline b.i.d., 0.5mg Varenicline b.i.d., and 1 other intervention for Tobacco Dependence and 2 related conditions. Completed, enrolled 313 participants across 2 sites.
Detailed Summary
The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
Study Details
Timeline
Interventions
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
Product that looks like active varenicline, but contains no active ingredient